Amwill Healthcare initial public offering (IPO) opened for subscription on February 5. The small and medium enterprise (SME) issue has been subscribed 5.73 times as of the third day of the bidding process.
Amwill is a derma-cosmetic development company that collaborates with contract manufacturers, distributors, and third-party product development agencies. These partnerships have helped the company build expertise in manufacturing, packaging, and distribution.
The Amwill Healthcare IPO has received 2,94,06,000 bids against the offered 54,03,600 shares by 6 pm on February 7.
On the third day of bidding, the retail segment of the issue was subscribed 4.77 times, while non-institutional investors- and QIB categories were subscribed 5.66 times and 7.8 times, respectively.
The shares of Amwill Healthcare IPO were trading at a Grey Market Premium (GMP) of ₹3 in the unlisted market on Thursday, indicating a 3% premium over the upper limit of the IPO price band of ₹117. The GMP has dipped from ₹14 per share on Tuesday.
'Grey market premium' indicates investors' readiness to pay more than the issue price.
Amwill Healthcare has set its IPO price between ₹105 and ₹111 per share, with a minimum lot size of 1,200 shares. The SME IPO will close for bidding on February 7.
The allocation includes 20 per cent reserved for institutional investors, 40 per cent for retail investors, and the remaining 40 per cent for non-institutional investors.
Amwill Healthcare is expected to complete the IPO share allotment process by February 10, with the listing set to take place on February 12.
Unistone Capital Pvt Ltd is the book running lead manager of the Amwill Healthcare IPO, while Bigshare Services Pvt Ltd is the registrar for the issue.The market maker for Amwill Healthcare IPO is Globalworth Securities Limited.
Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.